View Financial HealthAnbio Biotechnology 配当と自社株買い配当金 基準チェック /06Anbio Biotechnology配当金を支払った記録がありません。主要情報n/a配当利回り-0.5%バイバック利回り総株主利回り-0.5%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesBoard Change • May 20High number of new directorsIndependent Director Michael Zhang was the last director to join the board, commencing their role in 2026.お知らせ • Jan 27Anbio Biotechnology Announces Board and Committee Changes, Effective January 21, 2026Effective January 21, 2026, as approved by the Board of Directors, the Nominating Committee and the Compensation Committee of Anbio Biotechnology, Michael Zhang was appointed as a director, the Chair of Audit Committee, a member of Nominating Committee and a member of Compensation Committee. Michael Zhang would replace Kenneth Li as a director, the Chair of Audit Committee, a member of Nominating Committee and a member of Compensation Committee. Kenneth Li’s departure was not a result of any disagreement with the Company’s operations, policies or procedures. Michael Zhang has over 30 years’ experience in finance. He has worked as a managing partner, overseeing all corporate finance and investment-related matters at Healthcare Alpha Management since 2014. He obtained his bachelor’s degree in business from Indiana University Bloomington in 1996 and master’s degree in business administration from Yale University in 2004.Seeking Alpha • Oct 10Anbio Biotechnology's Hype And Hard Approvals Suggest A Stretched ValuationSummary Anbio Biotechnology is a medical device firm specializing in in-vitro diagnostics, with recent stock volatility and a thin public float. I believe they continue to face significant regulatory hurdles in both the EU (IVDR transition) and the US (FDA clearance). Likewise, NNNN trades at an extremely high valuation relative to its fundamentals and peers. It also has concentrated voting control on Class B shares. Thus, agency risks, regulatory uncertainties, and an expensive valuation nudge me towards "Sell" on the stock. Read the full article on Seeking Alphaお知らせ • Oct 10Anbio Biotechnology Showcases Diagnostic Portfolio At WSAVA 2025Anbio Biotechnology participated in the 50th World Small Animal Veterinary Association Congress (WSAVA 2025), an international gathering that brought together veterinarians, researchers, and industry representatives from more than 100 countries. The event provided a platform for Anbio to present its veterinary diagnostic portfolio and exchange views with partners across global markets. At WSAVA 2025, Anbio displayed five product lines: Fluorescence Immunoassay (FIA); Dry Chemistry; Molecular Diagnostics; Colloidal Gold Rapid Tests; Dry Chemiluminescence Immunoassay (CLIA). The portfolio generated interest among veterinarians, distributors, and industry participants. The dry chemistry and fluorescence immunoassay systems were noted for their precision and usability, while discussions with distributors reflected demand for accessible and accurate testing technologies in veterinary healthcare. A key feature was Anbio's molecular diagnostics platform, capable of producing multi-target real-time PCR results within 15 minutes. This function was highlighted as a practical option for the rapid detection of respiratory and infectious diseases in animals, where timely results are critical to clinical management. Delegates pointed to the relevance of such technologies in strengthening outbreak response and supporting routine diagnostic workflows. The exhibition also provided opportunities for Anbio to engage with existing and potential partners, discuss distribution strategies, and consider future product rollouts. These exchanges underlined the increasing role of point-of-care diagnostics in veterinary practice and emphasized the importance of international collaboration in expanding access to diagnostic tools. Looking ahead, Anbio will continue its global outreach. The company is scheduled to participate in the Wild West Vet Show 2025, taking place from October 15-18, 2025, in Reno, Nevada, USA. The exhibition will provide another opportunity to present its veterinary diagnostic portfolio. Anbio's participation in WSAVA 2025 reflects its continuing efforts in both human and veterinary diagnostics. By advancing practical and reliable testing solutions, the company contributes to improving healthcare outcomes in diverse settings worldwide.決済の安定と成長配当データの取得安定した配当: NNNNの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: NNNNの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Anbio Biotechnology 配当利回り対市場NNNN 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (NNNN)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.4%アナリスト予想 (NNNN) (最長3年)n/a注目すべき配当: NNNNは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: NNNNは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: NNNNの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: NNNNが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 10:55終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Anbio Biotechnology 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20High number of new directorsIndependent Director Michael Zhang was the last director to join the board, commencing their role in 2026.
お知らせ • Jan 27Anbio Biotechnology Announces Board and Committee Changes, Effective January 21, 2026Effective January 21, 2026, as approved by the Board of Directors, the Nominating Committee and the Compensation Committee of Anbio Biotechnology, Michael Zhang was appointed as a director, the Chair of Audit Committee, a member of Nominating Committee and a member of Compensation Committee. Michael Zhang would replace Kenneth Li as a director, the Chair of Audit Committee, a member of Nominating Committee and a member of Compensation Committee. Kenneth Li’s departure was not a result of any disagreement with the Company’s operations, policies or procedures. Michael Zhang has over 30 years’ experience in finance. He has worked as a managing partner, overseeing all corporate finance and investment-related matters at Healthcare Alpha Management since 2014. He obtained his bachelor’s degree in business from Indiana University Bloomington in 1996 and master’s degree in business administration from Yale University in 2004.
Seeking Alpha • Oct 10Anbio Biotechnology's Hype And Hard Approvals Suggest A Stretched ValuationSummary Anbio Biotechnology is a medical device firm specializing in in-vitro diagnostics, with recent stock volatility and a thin public float. I believe they continue to face significant regulatory hurdles in both the EU (IVDR transition) and the US (FDA clearance). Likewise, NNNN trades at an extremely high valuation relative to its fundamentals and peers. It also has concentrated voting control on Class B shares. Thus, agency risks, regulatory uncertainties, and an expensive valuation nudge me towards "Sell" on the stock. Read the full article on Seeking Alpha
お知らせ • Oct 10Anbio Biotechnology Showcases Diagnostic Portfolio At WSAVA 2025Anbio Biotechnology participated in the 50th World Small Animal Veterinary Association Congress (WSAVA 2025), an international gathering that brought together veterinarians, researchers, and industry representatives from more than 100 countries. The event provided a platform for Anbio to present its veterinary diagnostic portfolio and exchange views with partners across global markets. At WSAVA 2025, Anbio displayed five product lines: Fluorescence Immunoassay (FIA); Dry Chemistry; Molecular Diagnostics; Colloidal Gold Rapid Tests; Dry Chemiluminescence Immunoassay (CLIA). The portfolio generated interest among veterinarians, distributors, and industry participants. The dry chemistry and fluorescence immunoassay systems were noted for their precision and usability, while discussions with distributors reflected demand for accessible and accurate testing technologies in veterinary healthcare. A key feature was Anbio's molecular diagnostics platform, capable of producing multi-target real-time PCR results within 15 minutes. This function was highlighted as a practical option for the rapid detection of respiratory and infectious diseases in animals, where timely results are critical to clinical management. Delegates pointed to the relevance of such technologies in strengthening outbreak response and supporting routine diagnostic workflows. The exhibition also provided opportunities for Anbio to engage with existing and potential partners, discuss distribution strategies, and consider future product rollouts. These exchanges underlined the increasing role of point-of-care diagnostics in veterinary practice and emphasized the importance of international collaboration in expanding access to diagnostic tools. Looking ahead, Anbio will continue its global outreach. The company is scheduled to participate in the Wild West Vet Show 2025, taking place from October 15-18, 2025, in Reno, Nevada, USA. The exhibition will provide another opportunity to present its veterinary diagnostic portfolio. Anbio's participation in WSAVA 2025 reflects its continuing efforts in both human and veterinary diagnostics. By advancing practical and reliable testing solutions, the company contributes to improving healthcare outcomes in diverse settings worldwide.